ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers).
Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026.
In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting.
Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership in dermatology and L’Oréal’s expertise as the world’s leading beauty player. With a shared focus on skincare and skin health, innovation, and long-term growth, Galderma and L’Oréal are well positioned in the fast-growing, consumer-focused dermatology and beauty markets.
|
“Galderma continues to deliver impressive growth, strong innovation and category leadership across its broad, science-based dermatology portfolio. With strengthened commercial execution, continued platform and portfolio expansion, and an increasingly consumer-focused approach to innovation, we are rapidly scaling into a dermatology powerhouse. We are pleased with L’Oréal’s increased investment, which affirms our direction and the meaningful value creation we expect in the years ahead. As we move into 2026, we remain fully focused on our Integrated Dermatology Strategy and on serving our customers, consumers, and patients.”
FLEMMING ØRNSKOV, M.D., MPH |
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
i2c携手Wirex将加密货币预付卡引入美国
QpiAI宣布印度迎来量子时代曙光,推出25量子比
Jefferies和SMBC扩大并加强战略联盟
Movistar Chile通过SIAE MICROELET
全球电动车联盟发布电动车司机调查结果
把握行业机遇,博科测试IPO上市推动业绩增长
DRDM打造“痘肌修护”新理念,重新定义祛痘护
Canva庆祝赋予世界设计力量十周年
Omdia:2025年第四季度,全球智能手机市场增长
Kenvue发布首份《健康生活使命报告》
Streetbeat推出SmartPilot:由Ch
上饶银行滨江支行新春活动精彩纷呈
益博睿研究发现,新冠疫情以来线上活动增加了
《中国金银币标准目录》:一部帮你厘清中国金
全美顶尖律所ROSEN提醒Kandi
夏清华委员提案:弘扬万年珍珠文化 主动延伸
Fingerprints的20个非接触式生物识别卡试运行据点
Diligent发布AI风险要素解决方案以加快风险管理
KURA ONE推出小巧的罐装日本清酒
重庆五福盈引领山茶油进国际市场 首家通过联
数字化成未来教育重要部分 iEnglish让英语学习更
银牛视觉AI处理器采用芯原创新的ISP IP
“公厕革命”有新招 群众更方便
HistoSonics完成#HOPE4KIDNEY试验患